Bristol-myers Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRISTOL-MYERS, and when can generic versions of BRISTOL-MYERS drugs launch?
BRISTOL-MYERS has six approved drugs.
There are twenty-one US patents protecting BRISTOL-MYERS drugs.
There are three hundred and eighty-eight patent family members on BRISTOL-MYERS drugs in forty-five countries and fifty-five supplementary protection certificates in eighteen countries.
Summary for Bristol-myers
| International Patents: | 388 |
| US Patents: | 21 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 6 |
| Patent Litigation for Bristol-myers: | See patent lawsuits for Bristol-myers |
| PTAB Cases with Bristol-myers as patent owner: | See PTAB cases with Bristol-myers as patent owner |
Drugs and US Patents for Bristol-myers
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-004 | Jan 10, 2007 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-003 | Jan 17, 2003 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Bristol-myers Squibb | DAKLINZA | daclatasvir dihydrochloride | TABLET;ORAL | 206843-002 | Jul 24, 2015 | DISCN | Yes | No | 8,900,566 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol-myers | ABRAXANE | paclitaxel | POWDER;INTRAVENOUS | 021660-001 | Jan 7, 2005 | AB | RX | Yes | Yes | 8,314,156*PED | ⤷ Sign Up | ⤷ Sign Up | |||
| Bristol-myers | ISTODAX | romidepsin | POWDER;INTRAVENOUS | 022393-001 | Nov 5, 2009 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol-myers | VIDAZA | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 050794-001 | May 19, 2004 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol-myers | ABRAXANE | paclitaxel | POWDER;INTRAVENOUS | 021660-001 | Jan 7, 2005 | AB | RX | Yes | Yes | 7,820,788*PED | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bristol-myers
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-002 | Jan 17, 2003 | 6,755,784 | ⤷ Sign Up |
| Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-004 | Jan 10, 2007 | 6,869,399 | ⤷ Sign Up |
| Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-003 | Jan 17, 2003 | 6,869,399 | ⤷ Sign Up |
| Bristol-myers | ISTODAX | romidepsin | POWDER;INTRAVENOUS | 022393-001 | Nov 5, 2009 | 7,608,280 | ⤷ Sign Up |
| Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-003 | Jan 17, 2003 | 7,959,566 | ⤷ Sign Up |
| Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-002 | Jan 17, 2003 | 6,869,399 | ⤷ Sign Up |
| Bristol-myers | THALOMID | thalidomide | CAPSULE;ORAL | 020785-001 | Jul 16, 1998 | 6,561,977 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BRISTOL-MYERS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2006-09-25 |
| ➤ Subscribe | For Injection Suspension | 100 mg/vial | ➤ Subscribe | 2015-12-11 |
| ➤ Subscribe | Capsules | 50 mg and 100 mg | ➤ Subscribe | 2006-12-18 |
| ➤ Subscribe | Capsules | 150 mg | ➤ Subscribe | 2014-02-03 |
| ➤ Subscribe | Injection | 10 mg/vial | ➤ Subscribe | 2013-11-05 |
International Patents for Bristol-myers Drugs
Supplementary Protection Certificates for Bristol-myers Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2049522 | CA 2015 00003 | Denmark | ⤷ Sign Up | PRODUCT NAME: DACLATASVIR OG FARMACEUTISK ACCEPTABLE SALTE DERAF, SAERLIGT DACLATASVIR-DIHYDROCHLORID; REG. NO/DATE: EU/1/14/939 20140822 |
| 1951684 | C 2021 012 | Romania | ⤷ Sign Up | PRODUCT NAME: FEDRATINIB, SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIA, SAU UN HIDRAT ACCEPTABIL FARMACEUTIC AL ACESTUIA, IN PARTICULAR DICLORHIDRAT DE FEDRATINIB MONOHIDRAT; NATIONAL AUTHORISATION NUMBER: EU/1/20/1514; DATE OF NATIONAL AUTHORISATION: 20210208; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1514; DATE OF FIRST AUTHORISATION IN EEA: 20210208 |
| 2049522 | C20150003 00128 | Estonia | ⤷ Sign Up | PRODUCT NAME: DAKLATASVIIR;REG NO/DATE: EU/1/14/939 26.08.2014 |
| 2049522 | SPC/GB15/003 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DACLATASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY DACLATASVIR DIHYDROCHLORIDE; REGISTERED: UK EU/1/14/939/001-004 20140826 |
| 2049522 | 1590007-9 | Sweden | ⤷ Sign Up | PRODUCT NAME: DACLATASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY DACLATASVIR DIHYDROCHLORIDE; REG. NO/DATE: EU/1/14/939 20140826 |
| 1853250 | 300673 | Netherlands | ⤷ Sign Up | PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220 |
| 1853250 | 37/2014 | Austria | ⤷ Sign Up | PRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
